Ivermectin vs moxidectin for treating Strongyloides stercoralis infection: a systematic review
The aim was to assess the efficacy of ivermectin vs moxidectin for treating Strongyloides stercoralis infection. Ovid MEDLINE, Embase and Web of Science databases were searched for studies comparing ivermectin and moxidectin from inception to February 2024. The outcomes: elimination of infection or...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
|
| Series: | Parasitology |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0031182024001215/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841525580592316416 |
|---|---|
| author | Cesar Henriquez-Camacho Jose A. Pérez-Molina Dora Buonfrate Paola Rodari Eduardo Gotuzzo Benilde Luengo María Nieves Plana |
| author_facet | Cesar Henriquez-Camacho Jose A. Pérez-Molina Dora Buonfrate Paola Rodari Eduardo Gotuzzo Benilde Luengo María Nieves Plana |
| author_sort | Cesar Henriquez-Camacho |
| collection | DOAJ |
| description | The aim was to assess the efficacy of ivermectin vs moxidectin for treating Strongyloides stercoralis infection. Ovid MEDLINE, Embase and Web of Science databases were searched for studies comparing ivermectin and moxidectin from inception to February 2024. The outcomes: elimination of infection or parasitological cure, mortality and serious adverse events. We calculated odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous data. Heterogeneity was assessed using Chi2 test for statistical heterogeneity and results of the I2 statistic. Two trials met the inclusion criteria that included 821 adult participants. Both studies were conducted in southeast Asia (Cambodia and Laos). Neither trial included immunocompromised patients. The mean age of the participants ranged from 40 to 45 years old, with a similar distribution of males and females. For all participants, S. stercoralis infection was confirmed by Baermann method. The evidence was moderate for parasitological cure rate. Certainty was downgraded by 1 level because of imprecision. Moxidectin was not inferior to ivermectin: OR 0.67, 95% CI 0.36–1.25 (P = 0.21), I2 = 0%, 821 participants. No deaths were reported in either trial. One trial reported mild adverse events. In total, 153/726 (21%) participants had an adverse event. The most reported symptoms were abdominal pain and headache. There is evidence for moderate quality that moxidectin is non-inferior to, and as safe as ivermectin; however, more high-quality and well-designed trials are needed. For patients with some underlying immunosuppressive disorder, or in patients who are very young or very old, current data are insufficient to be recommended. |
| format | Article |
| id | doaj-art-db673bae5b604a728d2f80198f410501 |
| institution | Kabale University |
| issn | 0031-1820 1469-8161 |
| language | English |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Parasitology |
| spelling | doaj-art-db673bae5b604a728d2f80198f4105012025-01-17T09:42:28ZengCambridge University PressParasitology0031-18201469-81611710.1017/S0031182024001215Ivermectin vs moxidectin for treating Strongyloides stercoralis infection: a systematic reviewCesar Henriquez-Camacho0https://orcid.org/0000-0002-6714-5840Jose A. Pérez-Molina1Dora Buonfrate2https://orcid.org/0000-0003-0108-6822Paola Rodari3Eduardo Gotuzzo4Benilde Luengo5María Nieves Plana6Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain Internal Medicine Unit, Hospital Universitario de Móstoles, Madrid, SpainNational Reference Centre for Imported Tropical Diseases, Infectious Diseases Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain CIBERINFEC, Instituto de Salud Carlos III, Madrid, SpainDepartment of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, ItalyDepartment of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, ItalyFaculty of Medicine, Universidad Peruana Cayetano Heredia, Lima, PeruResearch Unit, Universidad Francisco de Vitoria (UFV), Madrid, SpainHealth Technology Assessment Unit, Hospital Universitario Ramón y Cajal and Universidad de Alcalá (IRYCIS), CIBER Epidemiology and Public Health (CIBERESP), Madrid, SpainThe aim was to assess the efficacy of ivermectin vs moxidectin for treating Strongyloides stercoralis infection. Ovid MEDLINE, Embase and Web of Science databases were searched for studies comparing ivermectin and moxidectin from inception to February 2024. The outcomes: elimination of infection or parasitological cure, mortality and serious adverse events. We calculated odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous data. Heterogeneity was assessed using Chi2 test for statistical heterogeneity and results of the I2 statistic. Two trials met the inclusion criteria that included 821 adult participants. Both studies were conducted in southeast Asia (Cambodia and Laos). Neither trial included immunocompromised patients. The mean age of the participants ranged from 40 to 45 years old, with a similar distribution of males and females. For all participants, S. stercoralis infection was confirmed by Baermann method. The evidence was moderate for parasitological cure rate. Certainty was downgraded by 1 level because of imprecision. Moxidectin was not inferior to ivermectin: OR 0.67, 95% CI 0.36–1.25 (P = 0.21), I2 = 0%, 821 participants. No deaths were reported in either trial. One trial reported mild adverse events. In total, 153/726 (21%) participants had an adverse event. The most reported symptoms were abdominal pain and headache. There is evidence for moderate quality that moxidectin is non-inferior to, and as safe as ivermectin; however, more high-quality and well-designed trials are needed. For patients with some underlying immunosuppressive disorder, or in patients who are very young or very old, current data are insufficient to be recommended.https://www.cambridge.org/core/product/identifier/S0031182024001215/type/journal_articleivermectinmoxidectinparasitological cureStrongyloides stercoralis |
| spellingShingle | Cesar Henriquez-Camacho Jose A. Pérez-Molina Dora Buonfrate Paola Rodari Eduardo Gotuzzo Benilde Luengo María Nieves Plana Ivermectin vs moxidectin for treating Strongyloides stercoralis infection: a systematic review Parasitology ivermectin moxidectin parasitological cure Strongyloides stercoralis |
| title | Ivermectin vs moxidectin for treating Strongyloides stercoralis infection: a systematic review |
| title_full | Ivermectin vs moxidectin for treating Strongyloides stercoralis infection: a systematic review |
| title_fullStr | Ivermectin vs moxidectin for treating Strongyloides stercoralis infection: a systematic review |
| title_full_unstemmed | Ivermectin vs moxidectin for treating Strongyloides stercoralis infection: a systematic review |
| title_short | Ivermectin vs moxidectin for treating Strongyloides stercoralis infection: a systematic review |
| title_sort | ivermectin vs moxidectin for treating strongyloides stercoralis infection a systematic review |
| topic | ivermectin moxidectin parasitological cure Strongyloides stercoralis |
| url | https://www.cambridge.org/core/product/identifier/S0031182024001215/type/journal_article |
| work_keys_str_mv | AT cesarhenriquezcamacho ivermectinvsmoxidectinfortreatingstrongyloidesstercoralisinfectionasystematicreview AT joseaperezmolina ivermectinvsmoxidectinfortreatingstrongyloidesstercoralisinfectionasystematicreview AT dorabuonfrate ivermectinvsmoxidectinfortreatingstrongyloidesstercoralisinfectionasystematicreview AT paolarodari ivermectinvsmoxidectinfortreatingstrongyloidesstercoralisinfectionasystematicreview AT eduardogotuzzo ivermectinvsmoxidectinfortreatingstrongyloidesstercoralisinfectionasystematicreview AT benildeluengo ivermectinvsmoxidectinfortreatingstrongyloidesstercoralisinfectionasystematicreview AT marianievesplana ivermectinvsmoxidectinfortreatingstrongyloidesstercoralisinfectionasystematicreview |